Objectives: To investigate the effect of topiramate on the steadystate plasma concentrations of the second-generation antipsychoticsVclozapine, olanzapine, risperidone, and quetiapineVin patients with schizophrenia or bipolar disorder. Methods: Thirty-eight outpatients on long-term treatment with clozapine (250Y500 mg/d, n = 10), olanzapine (10Y20 mg/d, n = 12), risperidone (3Y6 mg/d, n = 9), or quetiapine (200Y600 mg/d, n = 7) received adjunctive topiramate, gradually titrated up to a final dosage of 200 mg/d for 6 weeks. Pharmacokinetic assessments were made at baseline and at the end of treatment weeks 4 and 8 at topiramate dosages of 100 and 200 mg/d, respectively. Results: Plasma concentrations of clozapine and its metabolite (norclozapine), olanzapine, risperidone and its metabolite (9-hydroxy-risperidone), and quetiapine were not significantly modified during concomitant administration of topiramate. Adjunctive topiramate therapy was well tolerated in all groups. Conclusions: These findings indicate that topiramate, at the dosages recommended for use as a mood stabilizer, does not affect the plasma levels of the new antipsychoticsVclozapine, olanzapine, risperidone, and quetiapine

Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders

SANTORO, VINCENZA;BRUNO, ANTONIO;SPINA, Edoardo
2007-01-01

Abstract

Objectives: To investigate the effect of topiramate on the steadystate plasma concentrations of the second-generation antipsychoticsVclozapine, olanzapine, risperidone, and quetiapineVin patients with schizophrenia or bipolar disorder. Methods: Thirty-eight outpatients on long-term treatment with clozapine (250Y500 mg/d, n = 10), olanzapine (10Y20 mg/d, n = 12), risperidone (3Y6 mg/d, n = 9), or quetiapine (200Y600 mg/d, n = 7) received adjunctive topiramate, gradually titrated up to a final dosage of 200 mg/d for 6 weeks. Pharmacokinetic assessments were made at baseline and at the end of treatment weeks 4 and 8 at topiramate dosages of 100 and 200 mg/d, respectively. Results: Plasma concentrations of clozapine and its metabolite (norclozapine), olanzapine, risperidone and its metabolite (9-hydroxy-risperidone), and quetiapine were not significantly modified during concomitant administration of topiramate. Adjunctive topiramate therapy was well tolerated in all groups. Conclusions: These findings indicate that topiramate, at the dosages recommended for use as a mood stabilizer, does not affect the plasma levels of the new antipsychoticsVclozapine, olanzapine, risperidone, and quetiapine
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/1708750
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact